


## Genomics Enabled Medicine in Glioblastoma Trial


### PRINCIPAL INVESTIGATORS:



**Jeffrey M. Trent, Ph.D, FACMG**  
*President and Scientific Director*



**John D. Carpten, Ph.D**  
*Director, Integrated Cancer  
Genomics Division  
Deputy Director, Basic Sciences*



**David W. Craig, Ph.D**  
*Director, Neurogenomics Division  
Deputy Director, Bioinformatics*

### OBJECTIVES:

- Improve the current standard of care for brain tumor patients by using gene sequencing to select the best therapies for each individual patient.
- Identify genetic markers that can predict how brain tumor patients might respond to a specific therapy.
- Create a treatment guide for physicians using a computer database that tracks the patient's normal gene profile to the gene profile of their cancer and catalogs the drug therapies the patient is taking with information about their response.
- Study the safety and effectiveness of new drug combinations for brain tumor patients.
- Conduct clinical trials to determine if patients respond best to standard therapies or to treatments selected based on the gene profile of their cancer.

### PROGRESS REPORT:

- Completed gene sequencing of the first 15 of 20 patients in the study. Targeted for completion in 2013.
- Developed a database capable of tracking thousands of patient genetic profiles along with the response of their cancer to therapies.
- Two drugs have been successfully tested to treat brain tumors. Both drugs killed more than 95% of brain tumor cells when tested in animals. Five additional drugs have been identified as possible candidates for therapy.
- Working with the FDA, designed a clinical trial to compare standard therapies to therapies selected based on the patient's cancer gene profile. Developing partnerships with pharmaceutical companies to test their drugs for brain tumor patients.